4-TCPA
4-TCPA is a potent VEGFR2 inhibitor. 4-TCPA induces apoptosis and cell cycle arrest, likely through inhibition of VEGFR2 and EGFR signaling with additional effects on the mTOR pathway. 4-TCPA can inhibit the vitality and proliferation of various cancer cell lines. 4-TCPA can be used for the study of cancers such as lung cancer, breast cancer and leukemia[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; EGFR; mTOR; VEGFR
Related Pathways
Apoptosis; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C(NC1=CC=C(Cl)C=C1)CN2N=NC(CNC3=C4C=C(OCCOC)C(OCCOC)=CC4=NC=N3)=C2
Molecular Formula
C25H28ClN7O5
Molecular Weight
541.99
References & Citations
[1]Dehghan-Nayeri MJ, et al. Synthesis, characterization, anti-proliferative, and apoptotic activity of a novel quinazoline-containing 1,2,3-triazole toward three human cancer cells. Sci Rep. 2025 Jul 1;15 (1) :20852.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MTOR; VEGFR2/KDR/Flk-1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471231-100 1x 100 µL
Eosinophil Peroxidase (AHE-1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740012-100 1x 100 µL
Tyrosinase (T311), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040977-500 1x 500 µL
TGF-beta (1D11.16.8), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040373-100 1x 100 µL
Human IgM Immunoglobulin (IM373), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details